Your session is about to expire
← Back to Search
Monoclonal Antibodies
JNJ-77242113 for Plaque Psoriasis (FRONTIER 2 Trial)
Phase 2
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 40
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. These patients often need better treatments. The drug aims to improve their skin by changing how their immune system works.
Eligible Conditions
- Plaque Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to week 40
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 40
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 36
Secondary study objectives
Change From Baseline in PASI Total Score at Week 36
Change from Baseline in PSSD Signs Score at Week 36
Change from Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 36
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
6Treatment groups
Experimental Treatment
Group I: Group 6: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group II: Group 5: JNJ-77242113 Dose 3 BIDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
Group III: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
Group IV: Group 3: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Group V: Group 2: JNJ-77242113 Dose 2 QDExperimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
Group VI: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)Experimental Treatment1 Intervention
Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-77242113
2022
Completed Phase 2
~640
Find a Location
Who is running the clinical trial?
Janssen Research & Development, LLCLead Sponsor
1,007 Previous Clinical Trials
6,402,143 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
772 Previous Clinical Trials
3,980,170 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)
- Group 2: Group 2: JNJ-77242113 Dose 2 QD
- Group 3: Group 3: JNJ-77242113 Dose 3 QD
- Group 4: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)
- Group 5: Group 5: JNJ-77242113 Dose 3 BID
- Group 6: Group 6: JNJ-77242113 Dose 3 QD
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.